# Azithromycin for Meibomian Gland Disease

> **NCT03953118** · PHASE4 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 2 (actual)

## Conditions studied

- Dry Eye
- Neuropathic Eye Pain
- Ocular Microbiome
- Depression, Anxiety

## Interventions

- **DRUG:** Azithromycin Oral Product
- **DRUG:** Placebo Oral

## Key facts

- **NCT ID:** NCT03953118
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953118, "Azithromycin for Meibomian Gland Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03953118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*